Diabetes may weaken healing power of natural blood membranes

NCT ID NCT07672652

Completed Knowledge-focused Sponsor: Izmir Katip Celebi University Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study investigates whether type 2 diabetes changes the levels of key growth factors and inflammatory markers in Albumin Platelet-Rich Fibrin (Alb-PRF) membranes—a blood-derived material used to support wound healing and dental tissue repair. Researchers will compare Alb-PRF samples from 10 people with type 2 diabetes and 10 healthy volunteers, measuring interleukin-6, epidermal growth factor, and insulin-like growth factor-1. The goal is to understand if diabetes alters the biological makeup of these membranes, which could affect their effectiveness in regenerative treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Albumin platelet-rich fibrin (Alb-PRF) membranes
What this could lead to: If diabetes alters the composition of Alb-PRF, this could guide personalized regenerative treatments for people with diabetes.
What could go wrong: This is a small, early observational study with only 20 participants. It measures biomarkers, not clinical outcomes, so real-world impact is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 HEALTHY PARTICIPANTS

Contacts and locations

Locations

İzmir Katip Çelebi University

Izmir, Cigli, 35620, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.